Link: http://www.faccsf.com/Events/WIBMay10.htm

For this edition, we have the pleasure to welcome Belinda Tsao-Nivaggioli, Chief Executive Officer and Chairman of the board of the Avicena Group. She has raised over $170 million of grant money from NIH to move the clinical programs forward. Avicena is currently running the largest Phase III NIH funded trials in both Parkinson’s Disease and Huntington’s Disease. Prior to her current role, Dr. Tsao-Nivaggioli served as the company’s chief operating officer from 2002 to 2004. During her tenure as COO, the company expanded its intellectual property portfolio and built a valuable pipeline of products including several drug candidates for the treatment of various neurological disorders. As a result, the Avicena Group secured an orphan drug designation for its lead product, a therapeutic for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington’s disease.

Take part of this great networking event.
Tuesday, May 11th · 12:00-2:00 PM
Sofitel San Francisco Bay, Redwood City

Men are welcome!